Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2013

Open Access 01-06-2013 | Case Report

A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma

Authors: Kunihiro Tsuji, Kenichi Takemura, Keisuke Minami, Ryota Teramoto, Keisuke Nakashima, Shinya Yamada, Hisashi Doyama, Hisanori Oiwake, Kenkou Hasatani

Published in: Clinical Journal of Gastroenterology | Issue 3/2013

Login to get access

Abstract

We report on a case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. A 70-year-old man was admitted to our hospital with fatigue, myalgia and an elevated creatine phosphokinase level. He was diagnosed as rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. After discontinuation of sorafenib, his fatigue and myalgia resolved and his creatine phosphokinase level returned to normal. Rhabdomyolysis related to sorafenib treatment is rare adverse effect. This is the first detailed case report of rhabdomyolysis related to sorafenib treatment.
Literature
1.
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.PubMedCrossRef
2.
Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561–74.PubMedCrossRef
3.
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double blind, placebo controlled trial. Lancet Oncol. 2009;10:25–34.PubMedCrossRef
4.
Llovet J, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef
5.
Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67:272–83.PubMed
6.
Prendergast BD, George CF. Drug-induced rhabdomyolysis-mechanisms and management. Postgrad Med J. 1993;69:333–6.PubMedCrossRef
7.
Escudier B, Eisen T, Stadler WM, TARGET Study Group, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.PubMedCrossRef
8.
Escudier B, Eisen T, Stadier WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8.PubMedCrossRef
9.
10.
Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28:1054–60.PubMedCrossRef
11.
Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med. 2008;358:2746–7.PubMedCrossRef
12.
Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases. Ann Oncol. 2010;21:1926–7.PubMedCrossRef
13.
Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48:964–70.PubMedCrossRef
Metadata
Title
A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma
Authors
Kunihiro Tsuji
Kenichi Takemura
Keisuke Minami
Ryota Teramoto
Keisuke Nakashima
Shinya Yamada
Hisashi Doyama
Hisanori Oiwake
Kenkou Hasatani
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 3/2013
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-013-0381-2

Other articles of this Issue 3/2013

Clinical Journal of Gastroenterology 3/2013 Go to the issue

Case Report

Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature

Case Report

Barrett’s esophageal carcinoma consisting of undifferentiated carcinoma and differentiated adenocarcinoma: report of case

Case Report

Extensive 0-IIc (undifferentiated carcinoma) lesion around a gastric adenoma: a case report

Case Report

Pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm: a report of 8 cases

Case Report

Successful treatment of refractory gastric antral vascular ectasia using transcatheter arterial embolization

Case Report

Usefulness of multi-detector row computed tomography for management of duodenal varices by emergency balloon-occluded retrograde transvenous obliteration
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits